FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPRO\	/AL
OMB Number:	3235-0287
Estimated average but	rden
hours per response	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person * RENTON HOLLINGS				2. Issuer Name and Ticker or Trading Symbol RIGEL PHARMACEUTICALS INC [RIGL]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _X_ Director 10% Owner				
(Last) (First) (Middle) C/O RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD.				3. Date of Earliest Transaction (Month/Day/Year) 05/28/2010						Officer (giv	e title below)	Oth	er (specify belov	7)
(Street)				4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person				
SOUTH (Cit		NCISCO, CA 94 (State)												
(Cit	y)	(State)	(Zip)			Table 1	I - Non-Deri	vative Securition	es Acquirec	d, Disposed	of, or Bene	ficially Own	ed	
(Instr. 3) Date		2. Transaction Date (Month/Day/Year)	any	on Date, if		(.	4. Securities Acquired (A) or Disposed of (D (Instr. 3, 4 and 5)		Owned Follow Transaction(s)		d	Ownership Form:	Beneficial	
				(Month	/Day/Year)	Coo	de V A	(A) or (D)		(Instr. 3 and 4)			Direct (D) Or Indirect (I) (Instr. 4)	Ownership Instr. 4)
							in this	s who respon	equired to	o respond	unless the		ned SEC 1	474 (9-02)
							in this display	form are not r is a currently osed of, or Bend	equired to valid OME	o respond B control r	unless the		ned SEC 1	474 (9-02)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		3A. Deemed Execution Date, if	4. Transac Code	5. Number of Des	mber rivative ties red (A) posed	in this display	form are not rest a currently osed of, or Bendenvertible securercisable and Date	equired to valid OME eficially Ov- rities)	o respond B control r wned and Amount lying	unless the		Of 10. Ownersh Form of Derivativ Security: Direct (D or Indirec	11. Natur p of Indired Beneficia Ownersh (Instr. 4)
Derivative Security	Conversion or Exercise Price of Derivative	Date	3A. Deemed Execution Date, if any	4. Transac Code	5. Nution of Den Secur Acqui or Dis of (D) (Instr.	mber rivative ties red (A) posed	in this display quired, Display 6, options, co 6. Date Exc Expiration (Month/Da	form are not rest a currently cosed of, or Bendenvertible securercisable and Date y/Year)	required to valid OME eficially Overities) 7. Title and of Underly Securities	o respond B control r wned and Amount lying	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported	Of 10. Ownersh Form of Derivativ Security: Direct (D or Indirec	11. Natur p of Indired Beneficial Ownersh (Instr. 4)

Reporting Owners

	Relationships				
Reporting Owner Name / Address	Director	10% Owner	Officer	Other	
RENTON HOLLINGS C/O RIGEL PHARMACEUTICALS, INC. 1180 VETERANS BLVD. SOUTH SAN FRANCISCO, CA 94080	X				

Signatures

/s/ Dolly Vance (Attorney-In-Fact)	05/28/2010
Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The shares vest monthly for twelve (12) months from the date of grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.